Investor's Business Daily on MSN2h
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
STAT3h
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...
AstraZeneca reports better than expected profit on higher cancer drug sales
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
FiercePharma4h
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities investigate the company’s former China head. | As AstraZeneca faces an ongoing ...
STAT5h
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
AstraZeneca boss denies falling out with Labour despite scrapping £450m factory
The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool ...
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
Le Lézard6h
AstraZeneca's Full Year and Q4 2024 results
AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 ...
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...
AstraZeneca continues to ‘fully cooperate’ with Chinese authorities
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China — Update
AstraZeneca said it forecasts sales and earnings growth this year after fourth-quarter results beat expectations, as strength in its oncology business offset weak China sales, but warned of a ...